Analyst Activity – Morgan Stanley Reiterates Overweight on Radius Health (NASDAQ:RDUS) (NASDAQ:RDUS)

Analyst Ratings For Radius Health (NASDAQ:RDUS) (NASDAQ:RDUS)

Story continues below

Today, Morgan Stanley reiterated its Overweight rating on Radius Health (NASDAQ:RDUS) (NASDAQ:RDUS) with a price target of $59.00.

Some recent analyst ratings include

  • 3/23/2018-Morgan Stanley Reiterated Rating of Overweight .
  • 1/22/2018-Citigroup Reiterated Rating of Hold.
  • 10/6/2017-Goldman Sachs Reiterated Rating of Neutral .
  • 9/29/2017-Maxim Group Reiterated Rating of Positive.


  • On 3/2/2018 Growth N V Biotech, Major Shareholder, bought 80,000 with an average share price of $32.52 per share and the total transaction amounting to $2,601,600.00.
  • On 2/9/2018 Growth N V Biotech, Major Shareholder, bought 75,000 with an average share price of $34.38 per share and the total transaction amounting to $2,578,500.00.
  • On 11/14/2017 Growth N V Biotech, Major Shareholder, bought 50,000 with an average share price of $26.25 per share and the total transaction amounting to $1,312,500.00.
  • On 11/10/2017 Brent Hatzis-Schoch, VP, bought 1,778 with an average share price of $28.09 per share and the total transaction amounting to $49,944.02.
  • On 11/7/2017 Jesper Hoiland, Insider, bought 6,800 with an average share price of $29.04 per share and the total transaction amounting to $197,472.00.
  • On 11/3/2017 Growth N V Biotech, Major Shareholder, bought 50,000 with an average share price of $29.15 per share and the total transaction amounting to $1,457,500.00.
  • On 10/25/2017 Growth N V Biotech, Major Shareholder, bought 50,000 with an average share price of $32.85 per share and the total transaction amounting to $1,642,500.00.

Recent Trading Activity for Radius Health (NASDAQ:RDUS) (NASDAQ:RDUS)
Shares of Radius Health (NASDAQ:RDUS) closed the previous trading session at 33.47 down -0.36 1.06% with 43062 shares trading hands.

An ad to help with our costs